Literature DB >> 16323318

A pH-stability study of phoslactomycin B and analysis of the acid and base degradation products.

Suparna Das Choudhuri1, Sloan Ayers, William H Soine, Kevin A Reynolds.   

Abstract

Phoslactomycin B (PLM-B), a potent and selective inhibitor of serine threonine phosphatase is of interest for its antitumor, antifungal and antiviral activity. Described herein is an evaluation of the solution stability of phoslactomycin B at various pH and temperature conditions. Phoslactomycin B was produced from a NPI mutant strain of Streptomyces sp. HK-803 and purified by semi-preparative HPLC. A study of PLM-B degradation was carried out in the pH range of 2 approximately 10 at 30 degrees C and 50 degrees C using an HPLC assay. The PLM-B decomposition was observed to exhibit a U-shaped pH profile and demonstrated both acid and base-catalyzed decomposition. The decomposition could be described by the equation kOBS=kH x 10(-PH) + kOH x 10(pH-14) (kH=45 +/- 7 M(-1) h (-1); kOH= 448+/-73 M(-1h)(-1). PLM-B was found to be most stable at pH 6.63. The major acid and base products were separated and purified. Mass spectroscopic and NMR analysis revealed hydrolysis of the alpha, beta-unsaturated lactone provided the major degradation product under base conditions. Two other products in which hydration of the alpha, beta-unsaturated double bond preceded hydrolysis or methanolysis of the lactone were obtained. Under acidic condition MS and NMR analysis revealed that a dehydration step provided a C9-C11 phosphorinane derivative of PLM-B as one of the major products. The remaining acid degradation products were shown to be mixture of various dehydration products containing an additional double bond in central core of the PLM-B carbon skeleton. The major acid and base degradation products had dramatically reduced antifungal activity despite retaining the same structural core.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16323318     DOI: 10.1038/ja.2005.78

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  7 in total

1.  The plmS2-encoded cytochrome P450 monooxygenase mediates hydroxylation of phoslactomycin B in Streptomyces sp. strain HK803.

Authors:  Mohini S Ghatge; Kevin A Reynolds
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

2.  Silyl glyoxylates. Conception and realization of flexible conjunctive reagents for multicomponent coupling.

Authors:  Gregory R Boyce; Stephen N Greszler; Jeffrey S Johnson; Xin Linghu; Justin T Malinowski; David A Nicewicz; Andrew D Satterfield; Daniel C Schmitt; Kimberly M Steward
Journal:  J Org Chem       Date:  2012-03-23       Impact factor: 4.354

Review 3.  Genetic manipulation of the biosynthetic process leading to phoslactomycins, potent protein phosphatase 2A inhibitors.

Authors:  Mohini Ghatge; Nadaraj Palaniappan; Suparna Das Choudhuri; Kevin Reynolds
Journal:  J Ind Microbiol Biotechnol       Date:  2006-04-12       Impact factor: 3.346

4.  Polarity inversion of donor-acceptor cyclopropanes: disubstituted δ-lactones via enantioselective iridium catalysis.

Authors:  Joseph Moran; Austin G Smith; Ryan M Carris; Jeffrey S Johnson; Michael J Krische
Journal:  J Am Chem Soc       Date:  2011-10-31       Impact factor: 15.419

5.  Formal synthesis of leustroducsin B via Reformatsky/Claisen condensation of silyl glyoxylates.

Authors:  Stephen N Greszler; Justin T Malinowski; Jeffrey S Johnson
Journal:  Org Lett       Date:  2011-05-17       Impact factor: 6.005

6.  cis-Delta(2,3)-double bond of phoslactomycins is generated by a post-PKS tailoring enzyme.

Authors:  Nadaraj Palaniappan; Mamoun M Alhamadsheh; Kevin A Reynolds
Journal:  J Am Chem Soc       Date:  2008-08-21       Impact factor: 15.419

7.  Enhanced candicidal compound production by a new soil isolate Penicillium verruculosum MKH7 under submerged fermentation.

Authors:  Shruti Talukdar; Madhumita Talukdar; Manorama Buragohain; Archana Yadav; R N S Yadav; T C Bora
Journal:  BMC Microbiol       Date:  2016-12-09       Impact factor: 3.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.